Beit Jala Pharmaceutical(BJP) disclosed its financial statements for the third quarter of the year 2020.
| Disclosure Year | 2020 | 2019 | ||
| Disclosure Period | End of 3009 | End of 3009 | ||
| Disclosure Start Date | 01/01/2020 | 01/01/2019 | ||
| Disclosure End Date | 29/09/2020 | 29/09/2019 | ||
| Disclosure Type | Financial Disclosure | Financial Disclosure | ||
| Company's Name | Beit Jala Pharmaceutical | Beit Jala Pharmaceutical | ||
| Company Symbol | BJP | BJP | ||
| Sector | Industry Sector | Industry Sector | ||
| Currency | JD | JD | ||
| End date of legal disclosure period | 31/10/2020 | 31/10/2019 | ||
| Actual Disclosure Date | 22/10/2020 11:40:00 AM | 22/10/2019 08:24:00 AM | ||
| Hard Copy Disclosure | ||||
| Notes Display Source | Note ID Only | Note ID Only | ||
| Auditing Status | Unaudited | Unaudited | ||
| Net income in Cash Flow Statement | Income Before Tax | Income Before Tax |
The attached notes form part of these financial statements
| - | 2020 | 2019 | ||
| - | JD | JD | ||
| - | As a 29/09/2020 | As a 31/12/2019 | ||
| Note | Unaudited | Audited | ||
| Cash and cash equivalents | 747,939 | 1,000,699 | ||
| Accounts Receivable | 4,652,129 | 3,399,967 | ||
| Inventory | 2,281,157 | 2,616,526 | ||
| Tax advances | 410,255 | 223,293 | ||
| Prepaid expenses and other debit balances | 68,378 | 252,303 | ||
| Total Current Assets | 8,159,858 | 7,492,788 | ||
| Property, plant and equipment | 8,797,807 | 8,862,519 | ||
| Projects in progress | 1,236,989 | 213,371 | ||
| Total Fixed Assets | 10,034,796 | 9,075,890 | ||
| Total assets | 18,194,654 | 16,568,678 | ||
| Due to banks | 349,059 | 0 | ||
| Short term loans | 83,140 | 317,815 | ||
| Accounts Payable | 900,352 | 1,150,593 | ||
| Accrued expenses, Provisions, and Credit balances | 1,891,460 | 334,709 | ||
| Income Tax Provision | 243,819 | 189,259 | ||
| Total Current Liabilities | 3,467,830 | 1,992,376 | ||
| Long term loans | 2,060,276 | 1,599,362 | ||
| Deferred revenues after amortization | 37,895 | 46,484 | ||
| Provision for employees' indemnity | 797,791 | 802,617 | ||
| Total non-current liabilities | 2,895,962 | 2,448,463 | ||
| Total Liabilities | 6,363,792 | 4,440,839 | ||
| Paid-in Capital | 7,000,000 | 7,000,000 | ||
| Statutory reserve | 1,401,878 | 1,340,356 | ||
| voluntary reserve | 1,991,281 | 1,868,236 | ||
| Retained earnings | 907,475 | 1,526,818 | ||
| Foreign currency translation differences | 530,228 | 392,429 | ||
| Total Owners' Equity | 11,830,862 | 12,127,839 | ||
| Total Liabilities & Owners' Equity | 18,194,654 | 16,568,678 |
The attached notes form part of these financial statements
| - | 2020 | 2019 | ||
| - | JD | JD | ||
| - | End of 30092020 | End of 30092019 | ||
| Note | Unaudited | Unaudited | ||
| Sales | 6,228,744 | 6,174,848 | ||
| Cost of sales | (4,319,682) | (4,126,844) | ||
| Selling and Distribution Expenses | (748,236) | (771,300) | ||
| General and administrative expenses | (405,747) | (332,879) | ||
| Financing Income (Losses) | (34,740) | (29,046) | ||
| Other revenues (expenses) | 9,728 | 8,388 | ||
| Foreign currencies exchange gains/Losses | (6,273) | 55,447 | ||
| Net Income before tax | 723,794 | 978,614 | ||
| Income tax expense | (108,569) | (73,396) | ||
| Net Income after tax | 615,225 | 905,218 | ||
| Basic and diluted earnings (loss) per share | 0.088 | 0.129 | ||
| Foreign currency translation differences | 137,798 | 1,466,211 | ||
| Net Comprehensive Income | 753,023 | 2,371,429 |
The attached notes form part of these financial statements
| - | Paid-in Capital | Statutory Reserve | Voluntary Reserve | Change in Translation Difference | Retained Earnings | Total Owners' Equity | |
| Note | JD | JD | JD | JD | JD | JD | |
| 2020 | - | - | - | - | - | - | - |
|
Balance - Beginning of the period
|
7,000,000 | 1,340,356 | 1,868,236 | 392,429 | 1,526,818 | 12,127,839 | |
|
Net profit or (loss) for the period after tax
|
- | 61,522 | 123,044 | - | 430,659 | 615,225 | |
|
Foreign currency translation differences
|
- | - | - | 137,798 | - | 137,798 | |
|
Total Comprehensive Income for the Period
|
0 | 61,522 | 123,044 | 137,798 | 430,659 | 753,023 | |
|
Cash Dividends Paid
|
- | - | - | - | (1,050,000) | (1,050,000) | |
|
Balance - End of the period
|
7,000,000 | 1,401,878 | 1,991,280 | 530,227 | 907,477 | 11,830,862 | |
| 2019 | - | - | - | - | - | - | - |
| Balance - Beginning of the period | 7,000,000 | 1,204,025 | 1,595,575 | 213,769 | 1,632,018 | 11,645,387 | |
| Net profit or (loss) for the period after tax | - | 90,522 | 181,044 | - | 633,652 | 905,218 | |
| Foreign currency translation differences | - | - | - | 1,252,443 | - | 1,252,443 | |
| Total Comprehensive Income for the Period | 0 | 90,522 | 181,044 | 1,252,443 | 633,652 | 2,157,661 | |
| Cash Dividends Paid | - | - | - | - | (1,050,000) | (1,050,000) | |
| Balance - End of the period | 7,000,000 | 1,294,547 | 1,776,619 | 1,466,212 | 1,215,670 | 12,753,048 |
The attached notes form part of these financial statements
| - | 2020 | 2019 | ||
| - | JD | JD | ||
| - | End of 30092020 | End of 30092019 | ||
| Note | Unaudited | Unaudited | ||
| Net Income before/after tax | 723,794 | 978,614 | ||
| Depreciation and Amortization expense | 615,771 | 439,897 | ||
| Change in end of service allowance payments | 116,626 | 218,613 | ||
| Foreign currency translation differences | 137,799 | 1,252,442 | ||
| Change in Accounts Receivable | (1,252,162) | (852,919) | ||
| Change in inventory | 335,369 | (28,655) | ||
| Change in prepaid expenses and other debit balances | 183,925 | 146,401 | ||
| Letters of Credit and Guarantees | 0 | 300,327 | ||
| Change in Accounts Payable | (250,241) | 359,714 | ||
| Accrued expenses and other credit balances | 1,431,003 | (253,497) | ||
| Income Tax Reconciliation ( Previous Years) | (132,402) | (130,074) | ||
| Employees' indemnity paid | (121,452) | (32,043) | ||
| Net Cash Flow from Operating Activities | 1,788,030 | 2,398,820 | ||
| Purchase of Property, Plant and Equipment | (542,470) | (979,411) | ||
| Change in Projects in Progress | (1,023,618) | (943,798) | ||
| Net Cash Flow from Investing Activities | (1,566,088) | (1,923,209) | ||
| Due to banks | 349,059 | 0 | ||
| Long term loans | 226,239 | 199,949 | ||
| Dividends | (1,050,000) | (1,050,000) | ||
| Net Cash Flow from Financing Activities | (474,702) | (850,051) | ||
| Net change in cash and cash equivalents | (252,760) | (374,440) | ||
| Cash and cash equivalents, beginning of Period | 1,000,699 | 1,672,620 | ||
| Cash and cash equivalents, end of period | 747,939 | 1,298,180 |
The attached notes form part of these financial statements
Palestine Exchange: Received Disclosed Interim Financial Statements of Beit Jala Pharmaceutical(BJP) for the first nine months ended 30092020
The Palestine Exchange (PEX) received the Unaudited interim financial statements for first nine months of 2020 from Beit Jala Pharmaceutical(BJP).
According to financial statements for first nine months of 2020, Net profit after tax of the period reached 615,225 JD Compared with Net profit after tax 905,218 JD for 2019, a net decrease in profit of 32.04%.Total assets of the company reached 18,194,654 JD compared with total assets of 16,568,678 JD at the end of year 2019, a net increase of 9.81%.Total liabilities of the company reached 6,363,792 JD compared with total liabilities of 4,440,839 JD at the end of year 2019, a net increase of 43.30%. Net ownership equity of the company reached 11,830,862 JD compared with total owner equity of 12,127,839 JD at the end of year 2019, a net decrease of 2.45%.
The attached notes form part of these financial statements
Comments